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Purpose: To confirm the efficacy of ultrasound (US) guided radiofrequency ablation (RFA)
in the treatment of benign thyroid nodules, we evaluated as primary outcome the technical
efficacy and clinical success in a single center dataset. The secondary outcome was to
find a correlation between nodules’ pre-treatment features and volume reduction rate
(VRR) ≥75% at 12 months after RFA and during follow-up period.
Methods: This retrospective study included 119 consecutive patients (99 females, 20
males, 51.5 ± 14.4 years) with benign thyroid nodules treated in our hospital between
October 2014 and December 2018 with a mean follow-up of 26.8 months (range 3–48).
Clinical and US features before and after RFA were evaluated by a US examination at 1, 3,
6, 12 months and annually thereafter up to 48 months.
Results: The median pre-treatment volume was 22.4 ml; after RFA we observed a
statistically significant volume reduction from the first month (11.7 ml) to the last follow-up
(p < 0.001 for all follow-up times). The median VRR was 47.1, 55.3, 61.2, 67.6, 72.8, 71.3,
and 62.9% at 1, 3, 6, 12, 24, 36, and 48 months of follow-up respectively, showing a
progressive significant improvement up to 24 months (VRRs 1 vs 3 months, 3 vs 6 months
and 6 vs 12 months p < 0.001, 12 vs 24 months p = 0.05) while no differences at 24 vs 36
and 36 vs 48 months were observed. Symptoms improved significantly (complete resolution
64.35%, partial resolution 35.65%), and neck circumference was reduced as compared
to pre-treatment (p < 0.001). Lower pre-treatment neck circumference (37.5 vs 36.0 cm,
p = 0.01) was a positive predictor of VRR ≥75% at 12 months. Macrocystic echostructure
(HR 2.48, p 0.046) and pre-treatment volume >22.4 ml (HR 0.54, p 0.036) were found to be
independent positive and negative predictors of VRR ≥75% respectively. One-month post
RFA VRR ≥50% represented the best positive predictor of technical success.n.org May 2021 | Volume 12 | Article 6388801
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Frontiers in Endocrinology | www.froConclusions: This study confirmed the efficacy of RFA in the treatment of benign thyroid
nodules. In particular we show that by selecting macrocystic nodules smaller than 22.4 ml
better long-term response can be achieved, which is predicted by an early shrinkage of the
nodule.Keywords: predictive factors, efficacy of radiofrequency ablation, radiofrequency ablation (RFA), benign thyroid nodules,
volume reductionINTRODUCTION
Thyroid nodules are a relatively common clinical condition that
affects up to 65% of the general population with large variability
mostly originating from geographical heterogeneity and
sensitivity of diagnostic methods (1). The incidence seems to
be related to gender, insufficient iodine intake (2), and
particularly, age (3). In most cases, these lesions are not
symptomatic and, therefore, are diagnosed incidentally during
instrumental examinations performed for some other reasons
(4–6). Less frequently, thyroid nodules are diagnosed due to the
presence of a palpable nodule in the cervical region or related
symptomatology (i.e. compression trouble linked to the position
and/or size) or thyroid hyperfunction (7, 8).
Although most thyroid nodules are benign, treatment could
be required in the case of excessive size enlargement,
compressive and/or cosmetic symptoms (9), or anxiety for the
possibility of turning malignant (10, 11).
In these cases, the surgical approach represents the treatment
to be preferred for thyroid nodules with compressive symptoms,
even if it is known that neck surgery could lead to serious
complications, i.e. hypocalcemia and dysphonia (12, 13).
For these reasons, in the last two decades, image-guided
ablation procedures have been proposed. These procedures are
minimally invasive and are also applicable to patients with
contraindications to major surgery, or in patients who refuse
it. The most consolidated alternative are percutaneous ethanol
injection (PEI) (5, 14–16), laser ablation (LA) (17–20) and
radiofrequency ablation (RFA) (21–26); more recently, micro-
wave ablation (MW) and then high-intensity focused ultrasound
(HIFU) have been proposed (27, 28).
In particular, RFA has been recommended as a treatment to
be preferred for benign thyroid nodule by several guidelines (15,
29–32).
RFA of benign thyroid nodules have shown good results in
volume reduction rate (VRR), ranging from 33 to 58% one
month after treatment, and 51–85% up to six months,
improving most of nodule-related clinical symptoms (21, 23,
24, 33–37).
However, the way of predicting the outcome of RFA
treatments is still not well understood (38).
This study aimed to confirm the efficacy of RFA in the
treatment of benign thyroid nodules in a single center dataset
and to detect a significant correlation between pre-treatment
features, including clinical and ultrasonographic features, and
volume reduction rate (VRR) ≥75% at 12 months after the
procedure and then during all follow-ups.ntiersin.org 2MATERIALS AND METHODS
This retrospective observational study included 119 consecutive
patients referred to our Centre (Città della Salute e della Scienza
University Hospital in Turin) for RFA of thyroid benign nodules
from October 2014 to December 2018.
The inclusion criteria were: (a) patients aged 18 years or older;
(b) confirmation of benignity (Tir2, SIAPEC-IAP) (39) or
indeterminate lesions at low risk of malignancy (Tir3A) (39,
40) at two fine-needle aspiration cytology without echographic
features suspicious for malignancy and normal level of serum
calcitonin; (c) compressive or cosmetic symptoms in patients
with refusal or ineligibility for surgery; (d) patient underwent one
single-session RFA.
The exclusion criteria were: (a) malignant (Tir5) or suspicious
of malignancy (Tir3b-Tir4) thyroid nodules, (b) pregnancy.
The Institutional Review Boards of our hospital approved this
study, and patient consent was obtained in all cases.
Pre-Treatment Assessment
Clinical Evaluation
We categorized symptom and cosmetic scores as defined in a
previous consensus statement (41). Subjective compression
symptoms were assessed by a visual analogue scale (grades 0–
10) where 0 indicates the absence of compression-related
disorders and 10 indicates the maximum tolerable discomfort;
the cosmetic assessment was performed based on a four-point
scale: 1 = absence of palpable mass; 2 = palpable but not visible
mass; 3 = cosmetic problem during swallowing alone; 4 = easily
identifiable visible mass.
Neck circumference, expressed in centimeters (cm) and
measured by placing the tape measure in the middle of the
neck of the patient, was evaluated.
Biochemical Evaluation
Laboratory tests included: thyroid stimulating hormone (TSH),
serum free thyroxine (fT4), calcitonin, complete blood count,
coagulation tests, dibucaine number and cholinesterase, hepatic
and renal function. Additionally, all patients underwent baseline
electrocardiogram and vocal cord function assessment performed
by an otorhinolaryngologist before the ablation procedure.
Ultrasound Evaluation
Both transverse and longitudinal sonograms were obtained
by real-time imaging of the thyroid nodules using an Esaote
MyLab Twice real-time US system with a linear multifrequency
(7–14 mHz) probe. Still and video clip sonographic imagesMay 2021 | Volume 12 | Article 638880
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and two endocrinologists (RR and LP) with >10 years
of experience.
The sonographic findings were analyzed based on the current
guidelines (5, 15, 42) and reported as defined in a previous
consensus statement (41).
Diameters (anteroposterior, transverse, and longitudinal) of
each thyroid nodule were measured in centimeters (cm); the
nodular volume, expressed in milliliters (ml), was calculated by
the ultrasound machine on the basis of the diameters using the
ellipsoid volume formula (length × width × depth × 0.524).
The nodular echostructure was classified as solid (≤10% of
fluid component), microcystic (predominantly solid, 11–50% of
fluid component), macrocystic (predominantly cystic, 51–90%
of fluid component), cystic (>90% of fluid component), and
spongiform (nodules containing multiple small cysts smaller
than 5 mm interspersed within the solid tissue component for
nearly all the volume).
The nodules echogenicity was classified as hypoechoic, isoechoic,
or hyperechoic compared to the adjacent strap muscles of the neck.
Regarding nodular shape, nodules were divided into regular or taller
than wide. Nodular margins were categorized as smooth or
irregular. Calcifications were reported as present or absent.
Perinodular or intranodular vascularization was assessed by color
and power Doppler examination; stiffness was evaluated by
qualitative elastography (strain Elastosonography): the pressure is
exerted freehand through the ultrasound transducer. An
elastographic image (elasto-gram) is then produced, represented
as a color-coded image superimposed on the image in mode B (43,
44); in our study, we used the classification proposed by Rago et al.
(45). We defined the nodules with patterns 1 and 2 as soft; the
nodules corresponding to pattern 3 were classified as intermediate
elasticity and finally the nodules with patterns 4 and 5 were
considered hard.
RFA Procedure
Access to the procedures was carried out on a day hospital basis.
RFA procedures were performed by an operator with an
experience of >10 years (RG).
A single session of RFA was performed with the patient in a
supine position with mild neck extension. Patients underwent
treatment in a state of conscious sedation and were managed
with 0.75% ropivacaine around the thyroid gland for puncture
site anesthesia, always with ultrasound guidance.
We used an internally cooled electrode: 18 gauge, 7 or 10 cm
length with a 10 mm active tip (RFT(S) Tip/RFTP(S) RF Medical
Co.Ltd.) connected to a radiofrequency generator (Mygen M-3004).
A transisthmic approach method with the ‘moving shot
technique’ (29, 46) was adopted; the insertion of the needle-
electrode took place under freehand ultrasound guidance with a
mid-lateral path, in such a way as to direct the flow of energy
towards the lateral regions of the neck and away from areas at
risk due to contiguity of thermal injury, such as the inferior
laryngeal nerve and tracheoesophageal structures. The target
nodule is ideally divided into several ablation units prior to the
procedure. Starting from the deepest portion, the treatment is
carried out unit after unit by moving the needle towards the mostFrontiers in Endocrinology | www.frontiersin.org 3superficial portions. Due to the heat, necrosis is obtained and a
hyperechoic area is formed on the tip of the needle-electrode; the
generator shuts down power and impedance increases (47). The
needle is then gradually brought back along the electrode axis in
order to reach another tissue unit still to be treated. The
procedure ends when all the ideal units of the nodule have
been treated, which therefore appears completely hyperechoic.
The applied power and the actual time of treatment were
recorded at the end of each session; the mean power used during
the treatment was 55 Watt (W) and the treatment time about
15 min (49,500 J).
The procedures were monitored under the control of the B-
mode ultrasound method in real time to assess the correct
positioning of the needle-electrode within the lesion to be
treated. A transient and complete hyperecogenicity of the
target nodule, linked to heat-induced changes, represents the
parameter that identifies the end of the procedure (48). Before
removing the electrode, we performed an examination with
Contrast Enhanced Ultrasound (CEUS), SonoVue (Bracco,
Milan, Italy) to evaluate the extent of the necrosis area:
ablation was considered complete when the total volume of the
nodule appears not-vascularized. Once the needle-electrode was
extracted, a new ultrasound evaluation was performed to exclude
intra or extranodular complications.
The patients were observed for at least 3 h and were finally
discharged, in some selected cases with the prescription of oral
analgesic therapy.
Follow-Up
Post-RFA, patients were followed up by US and clinical evaluations
at 1, 3, 6 and 12 months after treatment and annually thereafter up
to 48 months. In each follow-up, US examination, symptom and
cosmetic score were evaluated while thyroid hormonal function was
assessed every year. Thyroid nodule volume was assessed, and the
volume reduction rate (VRR) of the treated nodule was calculated
based on the formula: VRR = [(initial volume − final volume) ×
100]/initial volume (26).
Study Outcome
The primary outcome was the therapeutic efficacy in terms of
volume reduction, VRR, and clinical success (41), defined as the
ability of the treatment to resolve the condition itself (compression
symptoms or cosmetic concerns); it was classified as complete (i.e.,
complete resolution of presenting symptoms), partial (i.e., symptom
improvement but still present), or absent (i.e., no symptom
improvement) and by modification of cosmetic score.
The secondary outcome was to find a significant correlation
between pre-treatment features of the nodules and technique
efficacy, defined as a volume reduction ≥75% at 12 months after
RFA and then during all follow-up period.
Statistical Analyses
According to the descriptive statistics, continuous variables with
normal distribution are expressed as mean ± standard deviation,
while non-parametric data as median with interquartile range.
Statistical differences between continuous variables were evaluated
with the Wilcoxon test for paired data or paired sample T-test.May 2021 | Volume 12 | Article 638880
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technique efficacy of RFA (VRR ≥ 75%) and the clinical and pre-
treatment ultrasound variables, a univariate analysis was conducted:
Fisher’s c2 test was used for binary and categorical variables, while,
for the continuous variables, in consideration of the non-normal
distribution of the data despite the good number of the sample
under study, the Mann–Whitney U test was assessed.
Secondly, for the comparison between multiple groups, the
Kruskal–Wallis H test was performed.
Finally, a multivariate logistic regression model was
constructed to confirm the existence of independent variables.
A dynamic analysis was then carried out, considering for each
subject the time, expressed in months, between the RFA
treatment and a volume reduction rate ≥75%, considered as
the technical success, or the time between treatment and the last
follow-up, in case of a volumetric reduction <75%. It was possible
to evaluate the cumulative incidence of success (VRR ≥ 75%) by
constructing the Kaplan–Meier curves, for a maximum follow-
up period of 48 months; by using the Log Rank test, the Kaplan–
Meier curves were then compared to evaluate the existence of
possible predictors. For continuous variables, this test was
performed by dividing the subjects into two categories based
on the median of distribution of the variable itself.
Finally, a multivariate Cox regression model was constructed
to confirm the presence of independent predictors.
The results were considered statistically significant if the p-
value was less than 0.05.
All statistical analyses were performed with STATA IC 10
(STATACORP, LP, Texas, USA) analytic software.RESULTS
Demographic and Sonographic
Characteristics of Thyroid Nodules
In this study, 99 out of 119 patients were females (83.20%); the
mean age at treatment was 51.5 ± 14.4 years with a mean follow-
up of 26.8 months (range 3– 48) after RFA. All patients had
normal TSH value. As regards the echostructural ultrasound
pattern, out of a total of 119 nodules, 29 (19.33%) were solid, 62
(52.1%) microcystic, nine (7.56%) macrocystic, and finally 11
(9.24%) spongiform. No cases of pure cystic nodules were
treated. Regarding the nodules with the first cytological result
of TIR3A, they were TIR2 at the second fine-needle aspiration
cytology in four out of five cases; only one case was confirmed as
TIR3A, GALECTIN 3 negative for immnocytochemistry. In this
case, the intermediate ultrasound risk nodule (15) with a size
>3 cm created tracheal compression. The patient refused surgery.
The baseline clinical and ultrasound characteristics of the patient
and nodules are summarized in Tables 1 and 2 respectively.
Volume and VRR
The median pre-treatment volume was 22.4 ml; after RFA we
observed a statistically significant volume reduction from the first
month (11.7 ml) to the last follow-up (p < 0.001 for all follow-up
times). The median VRR was 47.10% (range 31.30–56.50), 55.30%Frontiers in Endocrinology | www.frontiersin.org 4(range 46.70–68.80), 61.20% (range 52.0–73.60), 67.60% (range
53.90–79.20), 72.80% (range 56.60–83.20), 71.30% (range 56.10–
84.40), 62.90% (range 50.50–87.90), at 1, 3, 6, 12, 24, 36, and 48
months of follow-up respectively, showing a progressive significant
improvement up to 24 months of follow-up (VRRs 1 vs 3 months,
3 vs 6 months and 6 vs 12 months p < 0.001, 12 vs 24 months p =
0.05), while no significant differences between VVRs at 24 vs 36
months and 36 vs 48 months were observed (Figure 1).TABLE 1 | Pre-treatment clinical features of 119 thyroid RFA-treated nodules.
Clinical Features Total n = 119 (%)
Thyroid function Euthyroidism 100 (83.00)
Hypothyroidism 16 (13.50)
Hyperthyroidism 3 (2.50)





















Clinical Features Mean ± DS Median
(interquartile range)
Neck circumference (cm) 37.59 ± 3.57 37 (5.00)
Volume (ml) 25.25 ± 16.81 22.4 (20.70)May 2021 | VolumTABLE 2 | Ultrasonographic features of 119 thyroid RFA-treated nodules.
Ultrasound Features Total n = 119 (%)




Echogenicity Anechoic 0 (0.00)
Isoechoic 72 (60.50)
Hypoechoic 47 (39.50)
Markedly Hypoechoic 0 (0.00)
Margins Regular 116 (97.48)
Irregular 3 (2.52)
Calcifications Absent 80 (67.23)
Present 29 (32.77)
Shape Regular 119 (100)
Taller than wide 0 (0.00)








Volume (mL) ≤ 10 21 (17.65)
11-30 60 (50.42)
>30 38 (31.93)e 12 | Article 638880
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pre-treatment volume (41) (nodules ≤ 10, 10–30, and >30 ml), a
significant volume reduction was confirmed for each category
(p <0.001) (Figure 2). Furthermore, a significant improvement
in VRR was confirmed for each category (p < 0.001), and in the
comparison between the three groups, nodules with volume ≤10
ml had a higher VRR although in a non-statistically significant
way (Figure 3).
These results were also observed dividing the study sample
into four categories by pre-treatment echostructure (41); a
significant and progressive reduction in volume (p <0.001) and
improvement in VRR (p <0.001) were confirmed for each echo
pattern (Figure 2) and the nodules with macrocystic and
spongiform echostructure showed a higher VRR compared to
the other groups, but not statistically significance (Figure 3).
Clinical Success
Compressive symptoms (complete resolution 64.35%, partial
resolution 35.65%) and cosmetic score improved significantly
(p <0.001); a statistically significant reduction in neck circumference
was obtained at 6, 12, and 24 months post-treatment (p <0.001). The
mean pre-treatment neck circumference was 37.59 ± 3.57 cm and
decreased to 36.02 ± 3.43, 35.94 ± 3.02, and 35.79 ± 2.92 cm
respectively at 6, 12, and 24 months post-treatment.
Technical Success (VRR ≥75% at 12
Months) of Predictors’ Analysis
At the end of the global follow-up, 108 out of 119 patients
reached a VRR ≥50%.Frontiers in Endocrinology | www.frontiersin.org 5The patients were divided into two groups in relation to the
percentage of volumetric reduction obtained 12 months after
treatment: BR (Best Responders) group in case of VRR ≥75% (36
cases) and MR (Mild Responders) group in case of VRR <75%
(75 cases); subsequently, variables associated with VRR
(predictors) were analyzed.
The two groups did not show gender (p = 0.645) or age (p =
0.731) differences regardless of the cytological result.
Regarding neck circumference before treatment, the BR group
showed significantly lower values (p = 0.012) than the MR group.
In terms of volume, the BR group had lower nodular volumes than
theMRgroup,with a difference close to statistical significance (p= 0.063).
Analyzing nodular echostructure, the microcystic (p = 0.037)
and macrocystic (p = 0.022) nodules were associated with a
VRR ≥75% at 12 months.
Finally, we analyzed as a possible positive predictor of
response a VRR ≥50% at 1 month (VRR1m), considered the
minimum percentage of RFA success by recent literature (41);
this binary parameter was able to differentiate the two groups
(p < 0.001), and specifically, the BR group presented a greater
VRR1m than the MR group (56.30 vs 40.30%).
At multivariate logistic regression analysis, only VRR1m ≥50%
was confirmed as an independent predictor of a VRR ≥75% at 12
months after treatment (p = 0.001; OR: 6.91; CI: 2.23–21.45).
Time-Dependent Predictors’
Dynamic Analysis
The cumulative incidence of the technical success curve showed
that most of the RFA technical success was achieved within 12A B
FIGURE 1 | Nodules’ volume (A) and VRR (B) by time after RFA.A B
FIGURE 2 | Nodules’ volume by time after RFA stratified by pre-treatment volume (A) and echostructure (B).May 2021 | Volume 12 | Article 638880
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24 months (48%). After 24 months, although there was a slight
effectiveness improvement, it was significantly lower than the
effectiveness obtained within 24 months.
By comparing the Kaplan–Meier curves, we observe that
gender, older age (over the median value, 50 year), and larger
neck circumference (over the median value, 37.5 mm) do not
significantly affect the final outcome.
The pre-treatment volume is found to be a good predictor of
treatment efficacy (p = 0.01). The group of patients with a
nodular volume ≤22.4 ml (median) responded to the treatment
better than the others; on the contrary, a pre-treatment volume
>22.4 ml represented a negative predictor of success with an
overall efficacy that never exceeds 40%, Figure 4.
The pre-treatment volume was confirmed as a good predictor
of technical success even when stratified into three categories, as
proposed by the recent literature (p = 0.037), Figure 4.
In fact, a clear divergence of the three curves is observed; in
particular, the effectiveness of the treatment is found very low
(≤30%) in nodules >30 ml, while the technical success of RFA is
rapidly increasing in nodes <30 ml, especially if ≤10 ml (52% at
12 months, 60% at 24 months).
The comparison of the Kaplan–Meier curves shows that pre-
treatment echostructural patterns are able to separate the curves
with good reliability (p = 0.015). In particular, it shows how the
macrocystic echostructure positively modifies the outcome of theFrontiers in Endocrinology | www.frontiersin.org 6treatment with an efficacy of over 75% at 12 months and almost
total at 24 months, Figure 5.
Finally, taking into consideration the post-treatment
variables, Kaplan–Meier curves highlight that an early
volumetric reduction, as evidenced by a VRR ≥50% at 1 month
after treatment, was an excellent predictor of the achievement of
a VRR ≥75% during the whole follow-up (p = 0.0000), Figure 5.
At multivariate Cox regression model (p = 0.037, c2: 13.41),
macrocystic echostructure (HR 2.48, IC: 1.02–6.07 p 0.046) and
pre-treatment volume >22.4 ml (HR 0.54, IC: 0.31–0.96, p 0.036)
were found independent positive and negative predictors of
VRR ≥75% respectively.
One-month post RFA VRR>50% represented the best positive
predictor of technical success (HR: 2.48; CI: 1.40–4.39,
p = 0.002).DISCUSSION
RFA treatment of benign thyroid nodules aims at obtaining a
sufficient reduction of nodule volume for the regression of the
compressive symptoms and cosmetic disorder, keeping it as
stable as possible over time (15, 29, 30).
Our retrospective study confirmed the efficacy and safety of
RF ablation in a single large cohort of patients. Particularly, the
nodular volume showed a notable reduction as early as 1 monthA B
FIGURE 3 | Nodules’ VRR by time after RFA stratified by pre-treatment volume (A) and echostructure (B).FIGURE 4 | Kaplan–Meier curves of cumulative incidence of technical success (VRR ≥ 75%) by median volume (A) and three volume categories (B).May 2021 | Volume 12 | Article 638880
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and 72.80% at 24 months, according to the literature (49–52).
RFA treatment of benign nodules has been introduced into
clinical practice for a few years, so it still has a time-limited follow-
up (51, 53, 54). To this purpose, this study is expected to provide
additional information on the long-term result (up to 48 months) in
terms of volume reduction (VRR) and the possible correlation
between pre-treatment features and volume reduction rate.
First of all, our results (VRR at 3 months: 55.30%; VRR at 6
months: 61.20%) agree with some studies reporting that the
achievement of a VRR ≥50% is detectable already at 6 months
follow-up (52, 55). Then, in the literature, the technical success is
usually identified in a VRR ≥50% at 12 months (41) which, at best,
was achieved by 97.8% of patients (50). In our study, the achievement
of RFA technical success, defined as a VRR ≥75%, was found in 36%
of cases, with progressive improvement up to 24 months follow-up
(48%) and beyond, although less significant, achieving a VRR ≥75%
overall in the majority of treated nodules (57%).
Furthermore, according to our results, clinical success of the
treatment was complete in most cases within 12 months post-
RFA (64.35%); in the other cases the reduction was partial
(35.65%), indicating that none of the patients undergoing RFA
had an unsuccessful treatment, as highlighted by other authors
(51, 52, 55). However, evaluation of symptoms and clinical
success deriving from the volumetric reduction is subjectively
expressed, and the results are not completely reliable as
indicators of the success of the technique.
To date in the literature, some characteristics (47, 54), such as a
spongiform echostructure, a liquid component, a smaller initial pre-
treatment volume, an intense peripheral and intranodal pattern
vascularity of the nodule, have been found positively correlated with
a better result in terms of volumetric reduction, but no predictive
pre-treatment factors of RFA success have been identified definitely.
For this reason, we conducted a specific analysis to identify the
differences between clinical and ultrasound parameters in best
responder and mild responder patients.
Between the two groups, the indicative factors of a better
technical success proved to be:
- the echostructural pattern: in our series, the best technical
success was observed in macrocystic nodules (p = 0.015), inFrontiers in Endocrinology | www.frontiersin.org 7agreement with the literature (47, 56). The possible
explanation for this is that, as is known, the heating of a
tissue with a large fluid component, (be it colloid or blood)
produces a greater amount of vapor and a higher temperature
which favors the thermocoagulation process in the treated
nodule;
- the pre-treatment neck circumference, lower in the best
responder group, indicates that a larger neck is associated
with a worse response to the treatment. This data, never
considered in the literature, would deserve further prospective
studies in our view. Since there are no other systems beyond
the ultrasound to assess the goodness of the result, we have
tried to insert a linear dimensional parameter such as the
circumference of the neck in its maximum diameter. This
parameter, never considered in the literature, could offer
further important prospective studies. Certainly, this
parameter is associated with some confounding factors, as
weight changes; however, the measurement of the neck
circumference pre-treatment and during the follow-up
allows us to hypothesize that the volumetric reduction of a
nodule in the thyroid induces a remodeling of the anatomical
structures contained in the neck.
- the pre-treatment nodular volume: in best responding patients,
the nodules with volume ≤22.4 ml had a substantially better
response (p = 0.01). This result reinforces the hypothesis that
the greater volume reduction in nodules with lower basal
volume is probably due to reduced energy deposition during
RFA within large ones, which therefore results in a lower
response (32, 51).
In addition, in our cohort, we have pointed out that VRR1m is
a good predictor of technical success (reaching 50% in 56.30% of
responding patients; p = 0.0000); however, it should be
emphasized that this parameter, not mentioned in the
literature, although reliable, can only be evaluated after
treatment and, therefore, does not fall within the definition of
predictor of technical success.
Our study also highlights a progressive improvement in
technical success up to 24 months (48%) which remains stable
in the following months without however showing further
significant volume reductions. This data allows us toFIGURE 5 | Kaplan–Meier curves of cumulative incidence of technical success (VRR ≥ 75%) by echostructure (A) and VRR at 1 month (B).May 2021 | Volume 12 | Article 638880
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technique over a long period.
In clinical practice of management of symptomatic thyroid
nodules, these data could strengthen the indication of using RFA
on nodules with small volumes, without waiting for a volumetric
increase that could make this treatment less effective.
In addition, we observe that the measurement of the neck
circumference, despite possible confounding, combined with the
ultrasound evaluation, could provide important information on
the outcome of the procedure.
Finally, the strong correlation detected between VRR1m and
technical success shows the importance of monitoring the
nodular volumetric reduction during the first month post-RFA.
This parameter could be considered as an important indicator of
a successful outcome of the procedure (VRR1m >50%), or, on
the contrary, it can hypothesize a poor success of the procedure,
suggesting for example, to plan a second RFA or surgery
treatment in accordance with the patient’s opinion.
The major limitation is the retrospective nature of the study,
which however, has the strength of having been conducted in a
single center by the same personnel, thus lowering the risk of
interobserver bias.
With the limit of a retrospective study, regarding the neck
circumference as a factor to control in the follow-up, we have
reported only data on cases of changes in body weight, but we
have not adjusted the neck circumference for this parameter.
However, looking at these cases, we can state that in this study
the reduction in neck circumference occurred regardless of the
change in body weight.
Unfortunately, in this retrospective study we did not collect
data on thyroid autoantibodies. Further prospective studies
should consider the role of thyroiditis in structural changes of
the nodule after RFA.
An interesting future development could be the evaluation of
the energy delivered during RFA procedures in order to identify
energy values to be used for improving the final outcome.CONCLUSION
Based on current findings, the selection of nodules for pre-
treatment allows for better long-term responses, especially for
nodules with a lower pre-treatment volume (≤22.4 ml) and/or a
macrocystic echostructure; early shrinkage of the nodule, as
observed by a VRR1m ≥50% at one-month follow-up, is
shown to be a good predictor of positive RFA responses.Frontiers in Endocrinology | www.frontiersin.org 8Therefore, these factors represent the best positive predictors
of the radiofrequency thermal ablation technique on benign
thyroid nodules.
In conclusion, these parameters should always be evaluated
before considering any treatment with RFA to estimate the
probability of success or failure of the therapeutic method that
is targeted for each case. This result has important implications
from a clinical point of view: (i) patients can be made more
confident on the resolution of reported symptoms, and (ii) it
provides a valid alternative to the surgical approach while
permitting to gain relevant information on the need of
repeated treatment sessions, if these factors are absent.DATA AVAILABILITY STATEMENT
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